Table 2 |
||||||
| Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for the association between inflammatory variants and biliary stones, gallbladder and ampulla of Vater cancers in the Shanghai population | ||||||
| SNPs | rs# | Controls1n(%) | Casesn(%) | OR2 (95% CI) | p3 | FDR p4 |
| Biliary stones | ||||||
| VEGFA 9921bp 3' of STP A>G | rs9367173 | |||||
| GG | 539 (82.9) | 837 (86.8) | 1.0 | |||
| AG | 102 (15.7) | 126 (13.1) | 0.8 (0.60-1.07) | |||
| AA | 9 (1.4) | 6 (0.6) | 0.4 (0.14-1.15) | |||
| trend3 | 0.03 | 0.2 | ||||
| AG+AA | 111 (17.1) | 132 (13.7) | 0.77 (0.58-1.01) | |||
| VEGFA 6507bp 3' of STP G>A | rs6905288 | |||||
| AA | 357 (55.3) | 499 (51.8) | 1.0 | |||
| AG | 249 (38.5) | 386 (40.0) | 1.14 (0.92-1.41) | |||
| GG | 40 (6.2) | 81 (8.4) | 1.5 (1.00-2.25) | |||
| trend3 | 0.04 | 0.2 | ||||
| AG+GG | 289 (44.7) | 467 (48.4) | 1.19 (0.97-1.46) | |||
| Gallbladder cancer | ||||||
| IL8 -13985C>G | rs10805066 | |||||
| CC | 647 (81.1) | 187 (73.0) | 1.0 | |||
| CG | 140 (17.5) | 68 (26.6) | 1.67 (1.20-2.34) | |||
| GG | 11 (1.4) | 1 (0.4) | ||||
| trend3 | 0.03 | 0.2 | ||||
| CG+GG | 151 (18.9) | 69 (27.0) | 1.57 (1.13-2.18) | |||
| Ampulla of Vater Cancer | ||||||
| RNASEL IVS5+170G>A | rs672527 | |||||
| GG | 712 (83.6) | 39 (73.6) | 1.0 | |||
| AG | 133 (15.6) | 11 (20.8) | 1.54 (0.77-3.10) | |||
| AA | 7 (0.8) | 3 (5.7) | 8.40 (2.06-34.14) | |||
| trend3 | 0.01 | 0.09 | ||||
| AG+AA | 140 (16.4) | 14 (26.4) | 1.88 (0.99-3.57) | |||
| IL8 -13985C>G | rs10805066 | |||||
| CC | 685 (80.4) | 37 (69.8) | 1.0 | |||
| CG | 156 (18.3) | 13 (24.5) | 1.59 (0.82-3.07) | |||
| GG | 11 (1.3) | 3 (5.7) | 5.6 (1.47-21.42) | |||
| trend3 | 0.02 | 0.1 | ||||
| CG+GG | 167 (19.6) | 16 (30.2) | 1.83 (0.99-3.39) | |||
1 Gallbladder cancer cases compared with population controls who had a gallbladder, Ampulla of Vater cancer cases compared with all population controls and Biliary stone cases compared with population controls who did not have biliary stones; 2 Adjusted for gender and age group; 3 Test of trend for genotype under additive model; 4 Adjusted by using the Benjamini-Hochberg method.
Castro et al. BMC Cancer 2012 12:468 doi:10.1186/1471-2407-12-468
